News & Videos - GENOMIC HEALTH INC.

Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm PR Newswire NEW YORK, Oct. 17, 2019 NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related to merger agreements, inaccurate developments and/or financial projections....

Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Genomic Health, Inc. (GHDX) PR Newswire NEW YORK, Oct. 2, 2019 NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California , Case No. 3:19-cv-05929-SI, on behalf of shareholders of Genomic Health, Inc. ("Genomic" or the "Company") (NASDAQ:GHDX) who have been harmed by Genomic's and its...

New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate Oncotype DX® Test to a New Global Standard PR Newswire REDWOOD CITY, Calif., Sept. 30, 2019 REDWOOD CITY, Calif. , Sept. 30,...

Lifshitz & Miller LLP Announces Investigation of Bancorp of New Jersey, Inc., Dropbox, Inc., Ecology & Environment, Inc., Genomic Health, Inc., Ruhnn Holding Limited, Slack Technologies, Inc., SRC Energy Inc., and The RealReal, Inc. PR Newswire NEW YORK, Sept. 17, 2019 NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Bancorp of New Jersey , Inc. (BKJ) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Bancorp of New Jersey to ConnectOne...

Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Pivotal Software, Monotype Imaging Holdings, Navigant Consulting, and Genomic Health on behalf of Stockholders and Encourages Investors to Contact the Firm PR Newswire NEW YORK, Sept. 6, 2019 NEW YORK , Sept. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Pivotal Software, Inc. (NYSE: PVTL), Monotype Imaging...

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer - Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German PlanB studies, recognized as...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc. PR Newswire NEW YORK, July 29, 2019 NEW YORK , July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection with the proposed acquisition of the Company by Exact Science Corp. ("EXAS") (NASDAQ: EXAS). Under the terms of the agreement, Genomic Health...

Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale of Genomic Health, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, July 29, 2019 SAN DIEGO , July 29, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc. (NASDAQ: GHDX) ("Genomic") breached their fiduciary duties in connection with the proposed sale of the Company to Exact Sciences Corp. ("Exact Sciences"). On...

Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-Year 2019 Revenue and Net Income Guidance Earnings Call and Webcast Previously Scheduled for Thursday, August 1 Will Now Occur Today Monday, July 29 at 8 a.m. Eastern Time as a Joint Transaction Call with Exact Sciences PR Newswire...

Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 PR Newswire REDWOOD CITY, Calif., July 25, 2019 REDWOOD CITY, Calif. , July 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results. The call and webcast will follow the release of the second quarter...

Genomic Health Set to Join S&P SmallCap 600 PR Newswire NEW YORK, July 23, 2019 NEW YORK , July 23, 2019 /PRNewswire/ -- Genomic Health Inc. (NASD: GHDX) will replace Electronics For Imaging Inc. (NASD: EFII) in the S&P SmallCap 600 effective prior to the open of trading on Monday, July 29 . Siris Capital Group LLC acquired Electronics For Imaging in a deal that closed today. Genomic Health provides clinically actionable genomic information to personalize cancer treatment decisions....

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results PR Newswire REDWOOD CITY, Calif., June 20, 2019 REDWOOD CITY, Calif. , June 20, 2019 /PRNewswire/ -- Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement decision for the Oncotype DX Breast Recurrence Score ® test during...

Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision PR Newswire REDWOOD CITY, Calif., June 3, 2019 Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a...

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer PR Newswire REDWOOD CITY, Calif., June 3, 2019 New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD CITY, Calif. , June 3,...

Genomic Health to Present at the Jefferies 2019 Healthcare Conference PR Newswire REDWOOD CITY, Calif., May 29, 2019 REDWOOD CITY, Calif. , May 29, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2 p.m. Eastern Time . To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company's web site...

Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress Delivered $108.8M in Revenue and Growth of 17.4 Percent Achieved Significant Revenue Growth for All Key Product Areas Reported $13.0M in Profit and EPS of $0.34 Per Share on a Diluted Basis PR Newswire REDWOOD CITY, Calif., May 7, 2019 REDWOOD CITY, Calif. , May 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended March 31,...

Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019 PR Newswire REDWOOD CITY, Calif., April 30, 2019 REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results. The call and webcast will follow the release of the first quarter financial...

New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists PR Newswire REDWOOD CITY, Calif., March 25, 2019 REDWOOD CITY, Calif. , March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new...

Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basis and $39.7M on a Non-GAAP Basis Achieved 14th Consecutive Quarter of Improved Non-GAAP Profitability Guides to 14% Revenue Growth and 50% Non-GAAP Net Income Growth at High End of 2019 Outlook PR Newswire REDWOOD CITY, Calif., Feb. 20, 2019 REDWOOD...

Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019 PR Newswire REDWOOD CITY, Calif., Feb. 13, 2019 REDWOOD CITY, Calif. , Feb. 13, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results. The call and webcast will follow the...